{"gene":"HSD17B10","run_date":"2026-06-10T01:55:22","timeline":{"discoveries":[{"year":1999,"finding":"ERAB/HSD17B10 (HADH II) catalyzes NADH-dependent reduction of S-acetoacetyl-CoA (Km ~68 µM, Vmax ~430 µmol/min/mg), oxidation of 17β-estradiol, and oxidation of a variety of simple alcohols (C2–C10) in the presence of NAD+. Active-site mutagenesis (Y168G/K172G) abolished both enzymatic activity and Aβ-mediated cytotoxicity and prevented generation of malondialdehyde-protein and 4-hydroxynonenal adducts, establishing that the generalized alcohol dehydrogenase activity is required for Aβ-induced cell death.","method":"In vitro enzyme kinetics with purified recombinant protein; site-directed mutagenesis of catalytic domain; cell transfection assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with kinetics, active-site mutagenesis, and cellular functional validation in a single study","pmids":["9890977"],"is_preprint":false},{"year":1999,"finding":"Aβ peptide inhibits ERAB/HSD17B10 hydroxyacyl-CoA dehydrogenase activity in a mixed-type fashion (Ki ~1.2 µM using 3-hydroxybutyryl-CoA as substrate; KiES ~0.3 µM). The region of Aβ comprising residues 12–24 is required for inhibition. ERAB is localized to endoplasmic reticulum and mitochondria.","method":"In vitro enzyme inhibition kinetics with recombinant ERAB; peptide fragment analysis; subcellular fractionation/localization","journal":"FEBS letters","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro enzyme kinetics with mechanistic inhibition analysis, replicated binding observations across multiple studies","pmids":["10371197"],"is_preprint":false},{"year":2000,"finding":"Crystal structures of rat HADH II/ABAD were determined as: (1) binary complex with NADH at 2.0 Å, (2) ternary complex with NAD+ and 3-ketobutyrate at 1.4 Å, and (3) ternary complex with NADH and 17β-estradiol at 1.7 Å. The enzyme is a short-chain hydroxysteroid dehydrogenase with a Rossman fold. Ketobutyrate binding triggers closure of the active-site specificity loop; steroid substrate does not require loop closure. Rat HADH II/ABAD binds Aβ(1-40) with KD ~21 nM.","method":"X-ray crystallography; in vitro binding assay","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple high-resolution crystal structures with functional mechanistic interpretation, Aβ binding confirmed biophysically","pmids":["11023795"],"is_preprint":false},{"year":2004,"finding":"Crystal structure of human ABAD/HSD10 complexed with NAD+ and a small-molecule inhibitor revealed that the inhibitor occupies the substrate-binding site and forms a covalent adduct with the NAD+ cofactor, thereby blocking enzymatic activity.","method":"X-ray crystallography","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — high-resolution crystal structure with mechanistic interpretation of inhibitor binding mode","pmids":["15342248"],"is_preprint":false},{"year":2005,"finding":"In neurons from transgenic mice overexpressing both mutant APP and ABAD (Tg mAPP/ABAD), ABAD potentiates Aβ-induced mitochondrial dysfunction: spontaneous generation of H2O2 and superoxide, decreased ATP, cytochrome c release, caspase-3 activation, DNA fragmentation, and selective reduction of mitochondrial complex IV (cytochrome c oxidase, COX) activity. These changes were not present in Tg ABAD or Tg mAPP single-transgenic mice, establishing ABAD as a cofactor linking Aβ to mitochondrial oxidant stress.","method":"Transgenic mouse model (double vs single transgenic genetic epistasis); ROS assays; COX activity measurement; ATP quantification; cytochrome c release assay; caspase activity assay","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal functional readouts in a well-controlled genetic epistasis model, replicated in vivo and in vitro","pmids":["15665036"],"is_preprint":false},{"year":2007,"finding":"Surface plasmon resonance thermodynamic analysis showed that ABAD–Aβ association is driven by a favorable entropic change (ΔS = 300 ± 30 J mol−1 K−1) overcoming an unfavorable enthalpy (ΔH = 49 ± 7 kJ/mol), indicating hydrophobic interactions dominate. Saturation transfer difference NMR directly demonstrated that Aβ binding inhibits ABAD–NAD interaction, and conversely NAD inhibits Aβ binding, establishing that Aβ and NAD binding to ABAD are mutually exclusive. Aβ binding induces conformational changes in ABAD.","method":"Surface plasmon resonance (SPR) thermodynamic analysis; saturation transfer difference (STD) NMR","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — two orthogonal biophysical methods (SPR and NMR) in a single study establishing the mechanism of NAD/Aβ competition","pmids":["17253767"],"is_preprint":false},{"year":2007,"finding":"HSD17B10 encodes a mitochondrial multifunctional enzyme (HSD10) that catalyzes the 2-methyl-3-hydroxybutyryl-CoA dehydrogenation step in isoleucine catabolism and inactivates positive modulators of GABAA receptors (neuroactive steroids such as allopregnanolone). Missense mutations causing X-linked mental retardation and HSD10 deficiency impair these enzymatic functions.","method":"Enzyme activity assays on patient-derived samples; molecular genetic analysis","journal":"Molecular genetics and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical enzyme assays in patient cells with genetic validation, single lab review/original compilation","pmids":["17618155"],"is_preprint":false},{"year":2009,"finding":"The HSD10 E249Q mutation impairs subunit interactions, yielding allosteric enzyme kinetics (Hill coefficient ~1.3 for allopregnanolone oxidation). HSD10(E249Q) fails to catalyze dehydrogenation of 2-methyl-3-hydroxybutyryl-CoA and oxidation of allopregnanolone at low substrate concentrations, linking neurosteroid metabolic dysfunction—not isoleucine catabolism alone—to the neurological phenotype.","method":"Recombinant mutant protein expression; enzyme kinetics; comparison with wild-type activity","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with patient-derived mutations and kinetic analysis establishing allosteric mechanism","pmids":["19706438"],"is_preprint":false},{"year":2011,"finding":"HSD17B10 is an essential component of the mitochondrial RNase P complex, which removes 5'-extensions from mitochondrial tRNA precursors (tRNA processing). It also participates in the RNase P subcomplex that catalyzes N1-methylation of purines at position 9 of mitochondrial tRNAs.","method":"Biochemical characterization of the mitochondrial RNase P complex; tRNA processing assays","journal":"Journal of inherited metabolic disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional biochemical assays describing the role within a characterized complex, referenced from primary biochemical work","pmids":["22127393"],"is_preprint":false},{"year":2011,"finding":"The AG18051 small-molecule inhibitor partially blocks the Aβ–ABAD interaction (pull-down assay), prevents Aβ42-induced downregulation of ABAD's estradiol-producing activity (used as a functional readout), reduces Aβ42-induced mitochondrial respiration impairment, and reduces ROS, establishing that ABAD enzymatic activity contributes to Aβ toxicity through disruption of estradiol homeostasis in neurons.","method":"Pull-down assay; ABAD enzyme activity assay (estradiol measurement); mitochondrial respiration assay; ROS measurement; cell viability assays","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal functional assays in a single study, single lab","pmids":["22174920"],"is_preprint":false},{"year":2013,"finding":"Negative finding: Micromolar concentrations of monomeric or oligomerized Aβ inhibit mitochondrial tRNA 5'-end processing and position-9 methylation by the SDR5C1 (HSD17B10)-containing RNase P complex, but the same concentrations also inhibit related RNase P and methyltransferase activities that do NOT contain an SDR5C1 homolog. Therefore, the deleterious effect of Aβ on mitochondrial function cannot be explained by specific inhibition of the mitochondrial RNase P or its tRNA:m1R9 methyltransferase subcomplex via SDR5C1.","method":"In vitro RNase P and methyltransferase activity assays with recombinant components and Aβ titration","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1 / Moderate — rigorous in vitro reconstitution with appropriate controls demonstrating non-specificity; mechanistically informative negative result","pmids":["23755257"],"is_preprint":false},{"year":2015,"finding":"Pathogenic missense mutations in SDR5C1/HSD17B10 (HSD10 disease mutations) impair: (1) SDR5C1-dependent dehydrogenase activity, (2) mitochondrial tRNA 5'-end processing by the RNase P complex, and (3) N1-methylation of purines at tRNA position 9. Some mutations disrupt SDR5C1 homotetramerization and/or impair its interaction with TRMT10C (the methyltransferase subunit of mitochondrial RNase P).","method":"Recombinant mutant protein expression and biochemical characterization; tRNA processing assays; methyltransferase assays; protein–protein interaction assays","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with multiple patient mutations, multiple orthogonal assays (dehydrogenase, tRNA processing, methylation, protein interactions)","pmids":["25925575"],"is_preprint":false},{"year":2016,"finding":"A novel p.K212E mutation in HSD17B10 impairs SDR5C1-dependent mitochondrial RNase P activities (tRNA 5'-processing and position-9 methylation), but does not abolish dehydrogenase activity or MHBD function, indicating that pathogenicity in this case is due to impaired mitochondrial tRNA maturation rather than metabolic enzyme deficiency.","method":"In vitro tRNA processing and methylation assays with recombinant mutant protein; patient exome sequencing","journal":"RNA biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with patient mutation, multiple functional assays separating the two known functions","pmids":["26950678"],"is_preprint":false},{"year":2017,"finding":"Two novel patient mutations (p.V12L and p.V176M) in HSD17B10 reduce dehydrogenase activity, mitochondrial tRNA methyltransferase activity, and tRNA 5'-processing activity in vitro. p.V12L reduces protein stability; p.V176M impairs kinetics and TRMT10C/MRPP1 complex formation, revealing two distinct molecular mechanisms for pathogenic mutations.","method":"Recombinant mutant protein expression; enzyme kinetics; tRNA processing and methylation assays; protein stability and complex formation assays","journal":"Biochimica et biophysica acta. Molecular basis of disease","confidence":"High","confidence_rationale":"Tier 1 / Moderate — rigorous in vitro biochemical characterization with multiple orthogonal assays for two independent patient mutations","pmids":["28888424"],"is_preprint":false},{"year":2020,"finding":"HSD17B10 is acetylated at K79, K99, and K105 by the acetyltransferase CBP, and deacetylated by SIRT3. Acetylation of HSD17B10 regulates its dehydrogenase enzymatic activity and the formation of the mitochondrial RNase P complex. HSD17B10 acetylation state also affects cell growth and cell resistance under oxidative and starvation stress conditions.","method":"Co-IP; mass spectrometry identification of acetylation sites; site-directed mutagenesis; in vitro enzyme activity assay; cell-based functional assays","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP, mutagenesis, and functional assays; single lab, multiple methods","pmids":["32703935"],"is_preprint":false},{"year":2024,"finding":"HSD17B10 is succinylated at K99 by CPT1A. K99 succinylation maintains mitochondrial RNase P (MRPP1 complex) stability, and the K99R mutation disrupts HSD17B10 binding to CPT1A and MRPP1, impairs RNase P activity, and induces oxidative stress. ASIV restores CPT1A activity and K99 succinylation of HSD17B10, thereby preserving RNase P function in tubular epithelial cells.","method":"Succinylated proteomics; molecular docking; cell thermal shift assay; molecular dynamics simulation; site-directed mutagenesis (K99R); Co-IP; in vitro RNase P activity assay; in vivo mouse model","journal":"Phytotherapy research : PTR","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple methods including proteomics, mutagenesis, and functional assays; single lab","pmids":["39038923"],"is_preprint":false},{"year":2000,"finding":"Negative finding: Recombinant human ERAB/HSD17B10 showed no quinone reductase activity against several orthoquinones, with or without Aβ, indicating that Aβ-ERAB-induced lipid peroxidation observed in vivo is not mediated by quinone redox cycling.","method":"In vitro enzyme assay with recombinant human ERAB and orthoquinone substrates","journal":"Toxicology","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro assay, single lab, but mechanistically informative negative result","pmids":["10781884"],"is_preprint":false},{"year":1998,"finding":"ERAB/HSD17B10 contains a putative signal peptide sequence (identified by computational and comparative analysis across human, rodent, and bovine sequences) suggesting it is a type II integral membrane protein in vertebrates, potentially explaining its localization in secretory organelles and ability to bind Aβ.","method":"Computational sequence analysis; comparative vertebrate analysis","journal":"Biochemical and biophysical research communications","confidence":"Low","confidence_rationale":"Tier 4 / Weak — computational prediction only, no direct experimental validation of topology","pmids":["9712734"],"is_preprint":false},{"year":2011,"finding":"Behavioral stress (restraint) upregulates ABAD expression in mitochondria of the brain of Tg-APPswe/PS1dE9 mice. Knockdown of ABAD by siRNA in SH-SY5Y cells suppresses glucocorticoid-enhanced mitochondrial dysfunction and ROS accumulation, establishing that ABAD upregulation is required for stress-induced mitochondrial dysfunction in the context of Aβ pathology.","method":"siRNA knockdown; mitochondrial dysfunction assays; ROS measurement; transgenic mouse model","journal":"Free radical biology & medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function (siRNA) with defined functional readouts plus in vivo validation; single lab","pmids":["21382475"],"is_preprint":false}],"current_model":"HSD17B10 (ABAD/SDR5C1/MRPP2) is a mitochondrial short-chain dehydrogenase/reductase that functions as: (1) a metabolic enzyme catalyzing NAD+-dependent oxidation of 3-hydroxyacyl-CoA derivatives, neuroactive steroids (allopregnanolone, 17β-estradiol), and branched-chain fatty acid intermediates (including the MHBD step of isoleucine catabolism); (2) an essential structural and catalytic subunit of human mitochondrial RNase P, which cleaves 5'-extensions of mitochondrial tRNA precursors and methylates purines at tRNA position 9 (as part of the TRMT10C/MRPP1 subcomplex); and (3) an intracellular binding partner of Aβ peptide—interaction that is mutually exclusive with NAD+ binding, distorts the enzyme's structure, impairs its catalytic activity, and promotes mitochondrial oxidant stress and complex IV dysfunction; its enzymatic activity is regulated post-translationally by SIRT3-mediated deacetylation (at K79/K99/K105) and CPT1A-mediated K99 succinylation, both of which modulate its dehydrogenase activity and RNase P complex assembly."},"narrative":{"mechanistic_narrative":"HSD17B10 (ABAD/ERAB/SDR5C1/MRPP2) is a mitochondrial short-chain dehydrogenase/reductase that operates as a moonlighting enzyme bridging mitochondrial metabolism and tRNA maturation [PMID:9890977, PMID:22127393]. As a metabolic enzyme it adopts a Rossmann-fold and catalyzes NAD(H)-dependent reactions including reduction of S-acetoacetyl-CoA, oxidation of 3-hydroxyacyl-CoA derivatives, oxidation of 17β-estradiol, and broad-spectrum alcohol dehydrogenase activity, with ketobutyrate binding triggering closure of an active-site specificity loop [PMID:9890977, PMID:11023795]. In isoleucine catabolism it performs the 2-methyl-3-hydroxybutyryl-CoA dehydrogenation step and also inactivates GABAA-modulating neuroactive steroids such as allopregnanolone [PMID:17618155, PMID:19706438]. Independently of its catalytic activity, HSD17B10 is an essential homotetrameric subunit of mitochondrial RNase P, where together with TRMT10C/MRPP1 it enables 5'-end processing of mitochondrial tRNA precursors and N1-methylation of purines at tRNA position 9 [PMID:22127393, PMID:25925575]. Both functions are tuned post-translationally: SIRT3 deacetylates K79/K99/K105 (acetylated by CBP) and CPT1A succinylates K99 to regulate dehydrogenase activity and RNase P complex assembly [PMID:32703935, PMID:39038923]. Pathogenic missense mutations causing X-linked HSD10 disease impair these activities through distinct mechanisms—loss of dehydrogenase/MHBD activity, disrupted homotetramerization, reduced stability, or impaired TRMT10C binding and tRNA maturation—establishing that either metabolic or RNase P dysfunction can drive the neurological phenotype [PMID:19706438, PMID:25925575, PMID:26950678, PMID:28888424]. HSD17B10 also binds Aβ peptide via a hydrophobically-driven interaction (KD ~21 nM) that is mutually exclusive with NAD+, distorts the enzyme, and potentiates Aβ-induced mitochondrial oxidant stress, cytochrome c release, and selective complex IV deficiency [PMID:11023795, PMID:15665036, PMID:17253767]; controlled in vitro work establishes that Aβ inhibition of RNase P is not SDR5C1-specific and therefore does not account for this toxicity [PMID:23755257].","teleology":[{"year":1999,"claim":"Established that HSD17B10 is a catalytically active NAD(H)-dependent dehydrogenase and that this enzymatic activity is mechanistically required for Aβ-induced cytotoxicity, linking an enzyme to neurodegenerative cell death.","evidence":"In vitro enzyme kinetics with recombinant protein, active-site mutagenesis (Y168G/K172G), and cell transfection cytotoxicity assays","pmids":["9890977"],"confidence":"High","gaps":["Did not resolve which physiological substrate mediates toxicity","Mechanism connecting catalysis to lipid peroxidation adducts left undefined"]},{"year":1999,"claim":"Defined the kinetic mode of Aβ inhibition of HSD17B10 and the Aβ region required, framing the enzyme as a direct intracellular Aβ target.","evidence":"In vitro enzyme inhibition kinetics with 3-hydroxybutyryl-CoA, Aβ peptide fragment analysis, and subcellular fractionation","pmids":["10371197"],"confidence":"High","gaps":["ER vs mitochondrial localization not reconciled with later mitochondrial assignment","Structural basis of Aβ binding not yet defined"]},{"year":2000,"claim":"Solved the catalytic architecture, showing a Rossmann-fold dehydrogenase with a substrate-specificity loop and quantifying high-affinity Aβ binding, providing structural mechanism for cofactor and substrate handling.","evidence":"X-ray crystallography of binary and ternary complexes (NADH, NAD+/3-ketobutyrate, NADH/17β-estradiol) plus in vitro Aβ binding","pmids":["11023795"],"confidence":"High","gaps":["Aβ binding site not mapped on the structure","Human enzyme structure not yet determined here (rat ortholog)"]},{"year":2000,"claim":"Ruled out quinone redox cycling as the source of Aβ-ABAD-induced lipid peroxidation, narrowing candidate toxicity mechanisms.","evidence":"In vitro orthoquinone reductase assays with recombinant human ERAB +/- Aβ","pmids":["10781884"],"confidence":"Medium","gaps":["Negative result does not identify the actual oxidant-generating mechanism","Single lab in vitro assay"]},{"year":2004,"claim":"Demonstrated a druggable active site by capturing an inhibitor forming a covalent adduct with the NAD+ cofactor in the human enzyme, establishing a structural strategy to block activity.","evidence":"X-ray crystallography of human ABAD with NAD+ and a small-molecule inhibitor","pmids":["15342248"],"confidence":"High","gaps":["Cellular efficacy of inhibitor not addressed in this structural study","Selectivity over other SDRs not established"]},{"year":2005,"claim":"Provided in vivo genetic proof that ABAD acts as a cofactor converting Aβ into mitochondrial dysfunction, including selective complex IV loss.","evidence":"Double vs single transgenic mouse epistasis (mAPP/ABAD), ROS, COX activity, ATP, cytochrome c release, caspase-3 assays","pmids":["15665036"],"confidence":"High","gaps":["Molecular cause of selective complex IV vulnerability not defined","Did not distinguish loss of enzyme function from gain of toxic complex"]},{"year":2007,"claim":"Resolved the thermodynamics and exclusivity of Aβ binding, showing hydrophobically-driven Aβ association is mutually exclusive with NAD+, defining a competitive inactivation mechanism.","evidence":"Surface plasmon resonance thermodynamics and saturation transfer difference NMR","pmids":["17253767"],"confidence":"High","gaps":["Atomic-resolution Aβ-bound structure still lacking","Quantitative contribution of conformational distortion to toxicity unquantified"]},{"year":2007,"claim":"Connected HSD17B10 metabolic functions—isoleucine catabolism and neurosteroid inactivation—to X-linked mental retardation/HSD10 deficiency, broadening its physiological remit beyond Alzheimer biology.","evidence":"Enzyme activity assays on patient-derived samples and molecular genetic analysis","pmids":["17618155"],"confidence":"Medium","gaps":["Relative contribution of each metabolic function to disease unresolved","Compilation-style evidence rather than single reconstitution"]},{"year":2009,"claim":"Showed a disease mutation can disrupt subunit interactions and confer allosteric kinetics, implicating neurosteroid metabolic failure rather than isoleucine catabolism alone in pathology.","evidence":"Recombinant E249Q mutant kinetics (Hill coefficient ~1.3) versus wild-type","pmids":["19706438"],"confidence":"High","gaps":["In vivo neurosteroid levels in patients not measured here","Generalizability to other mutations not tested"]},{"year":2011,"claim":"Established a wholly distinct, non-metabolic role for HSD17B10 as an essential subunit of mitochondrial RNase P, coupling it to tRNA 5'-processing and position-9 methylation.","evidence":"Biochemical characterization of the mitochondrial RNase P complex and tRNA processing assays","pmids":["22127393"],"confidence":"Medium","gaps":["Catalytic vs structural contribution of HSD17B10 to RNase P not separated","Stoichiometry within the complex not defined here"]},{"year":2011,"claim":"Provided loss-of-function evidence that ABAD upregulation is required for stress-induced mitochondrial dysfunction under Aβ pathology, linking glucocorticoid stress to the ABAD-Aβ axis.","evidence":"siRNA knockdown in SH-SY5Y cells, ROS and mitochondrial dysfunction assays, plus Tg-APPswe/PS1dE9 mouse model","pmids":["21382475"],"confidence":"Medium","gaps":["Transcriptional mechanism of stress-induced ABAD upregulation unknown","Single cell line for knockdown"]},{"year":2011,"claim":"Showed a small-molecule disruptor of the Aβ-ABAD interaction rescues mitochondrial respiration and estradiol homeostasis, supporting enzymatic activity as a therapeutic node in Aβ toxicity.","evidence":"Pull-down, estradiol-based enzyme activity readout, mitochondrial respiration, ROS, and viability assays with AG18051","pmids":["22174920"],"confidence":"Medium","gaps":["Only partial blockade of interaction achieved","In vivo efficacy not tested; single lab"]},{"year":2013,"claim":"Demonstrated that Aβ inhibition of the SDR5C1-containing RNase P is non-specific, excluding RNase P inhibition as the mechanism of Aβ mitochondrial toxicity.","evidence":"In vitro RNase P and methyltransferase assays comparing SDR5C1-containing and non-SDR5C1 complexes with Aβ titration","pmids":["23755257"],"confidence":"High","gaps":["Does not identify the bona fide Aβ target for mitochondrial dysfunction","Confined to in vitro reconstituted activities"]},{"year":2015,"claim":"Unified the disease mechanism by showing pathogenic mutations simultaneously impair dehydrogenase activity, RNase P tRNA processing, methylation, homotetramerization, and TRMT10C interaction.","evidence":"Recombinant mutant proteins with dehydrogenase, tRNA processing, methyltransferase, and protein interaction assays","pmids":["25925575"],"confidence":"High","gaps":["Which deficit dominates clinically per mutation not resolved","Structural basis of disrupted tetramerization not shown"]},{"year":2016,"claim":"Dissociated the two functions in vivo by identifying a mutation (K212E) that impairs RNase P activities while sparing dehydrogenase/MHBD function, proving tRNA maturation defects alone can be pathogenic.","evidence":"In vitro tRNA processing and methylation assays with recombinant K212E and patient exome sequencing","pmids":["26950678"],"confidence":"High","gaps":["How a single residue selectively affects RNase P but not catalysis structurally unexplained","Single patient"]},{"year":2017,"claim":"Defined two distinct molecular routes to pathogenicity—protein destabilization versus impaired kinetics and complex formation—for additional patient mutations.","evidence":"Recombinant V12L and V176M mutant kinetics, tRNA processing/methylation, stability, and MRPP1 complex formation assays","pmids":["28888424"],"confidence":"High","gaps":["In vivo consequences of each mechanism not measured","Limited to two mutations"]},{"year":2020,"claim":"Revealed post-translational acetylation control of HSD17B10, with CBP and SIRT3 setting K79/K99/K105 acetylation to regulate both dehydrogenase activity and RNase P assembly and stress resistance.","evidence":"Co-IP, mass spectrometry site mapping, site-directed mutagenesis, in vitro activity, and cell-based stress assays","pmids":["32703935"],"confidence":"Medium","gaps":["Physiological stimuli driving acetylation changes not defined","Single lab; in vivo relevance untested"]},{"year":2024,"claim":"Added a second PTM layer by showing CPT1A-mediated K99 succinylation maintains RNase P (MRPP1) stability and protects against oxidative stress in tubular epithelial cells.","evidence":"Succinyl-proteomics, docking, thermal shift, MD simulation, K99R mutagenesis, Co-IP, RNase P activity, and mouse model","pmids":["39038923"],"confidence":"Medium","gaps":["Interplay between K99 acetylation and succinylation unresolved","Single lab; mechanism of CPT1A targeting to HSD17B10 unclear"]},{"year":null,"claim":"The bona fide intracellular substrate and molecular event by which Aβ binding to HSD17B10 selectively impairs complex IV and drives oxidant stress remains unidentified.","evidence":"","pmids":[],"confidence":"High","gaps":["RNase P inhibition excluded as the toxic mechanism","No atomic-resolution Aβ-bound HSD17B10 structure","Causal substrate linking catalysis to mitochondrial damage undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016491","term_label":"oxidoreductase activity","supporting_discovery_ids":[0,2,6,7]},{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[8,11]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[8,11]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[1,4,8]}],"pathway":[{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[8,11]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,6,7]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[4,11]}],"complexes":["mitochondrial RNase P"],"partners":["TRMT10C","CPT1A","SIRT3","CBP"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q99714","full_name":"3-hydroxyacyl-CoA dehydrogenase type-2","aliases":["17-beta-estradiol 17-dehydrogenase","2-methyl-3-hydroxybutyryl-CoA dehydrogenase","MHBD","3-alpha-(17-beta)-hydroxysteroid dehydrogenase (NAD(+))","3-hydroxy-2-methylbutyryl-CoA dehydrogenase","3-hydroxyacyl-CoA dehydrogenase type II","3alpha(or 20beta)-hydroxysteroid dehydrogenase","7-alpha-hydroxysteroid dehydrogenase","Endoplasmic reticulum-associated amyloid beta-peptide-binding protein","Mitochondrial ribonuclease P protein 2","Mitochondrial RNase P protein 2","Short chain dehydrogenase/reductase family 5C member 1","Short-chain type dehydrogenase/reductase XH98G2","Type II HADH"],"length_aa":261,"mass_kda":26.9,"function":"Mitochondrial dehydrogenase involved in pathways of fatty acid, branched-chain amino acid and steroid metabolism (PubMed:10600649, PubMed:12917011, PubMed:18996107, PubMed:19706438, PubMed:20077426, PubMed:25925575, PubMed:26950678, PubMed:28888424, PubMed:9553139). Acts as (S)-3-hydroxyacyl-CoA dehydrogenase in mitochondrial fatty acid beta-oxidation, a major degradation pathway of fatty acids. Catalyzes the third step in the beta-oxidation cycle, namely the reversible conversion of (S)-3-hydroxyacyl-CoA to 3-ketoacyl-CoA. Preferentially accepts straight medium- and short-chain acyl-CoA substrates with highest efficiency for (3S)-hydroxybutanoyl-CoA (PubMed:10600649, PubMed:12917011, PubMed:25925575, PubMed:26950678, PubMed:9553139). Acts as 3-hydroxy-2-methylbutyryl-CoA dehydrogenase in branched-chain amino acid catabolic pathway. Catalyzes the oxidation of 3-hydroxy-2-methylbutanoyl-CoA into 2-methyl-3-oxobutanoyl-CoA, a step in isoleucine degradation pathway (PubMed:18996107, PubMed:19706438, PubMed:20077426). Has hydroxysteroid dehydrogenase activity toward steroid hormones and bile acids. Catalyzes the oxidation of 3alpha-, 17beta-, 20beta- and 21-hydroxysteroids and 7alpha- and 7beta-hydroxy bile acids (PubMed:10600649, PubMed:12917011). Oxidizes allopregnanolone/brexanolone at the 3alpha-hydroxyl group, which is known to be critical for the activation of gamma-aminobutyric acid receptors (GABAARs) chloride channel (PubMed:19706438, PubMed:28888424). Has phospholipase C-like activity toward cardiolipin and its oxidized species. Likely oxidizes the 2'-hydroxyl in the head group of cardiolipin to form a ketone intermediate that undergoes nucleophilic attack by water and fragments into diacylglycerol, dihydroxyacetone and orthophosphate. Has higher affinity for cardiolipin with oxidized fatty acids and may degrade these species during the oxidative stress response to protect cells from apoptosis (PubMed:26338420). By interacting with intracellular amyloid-beta, it may contribute to the neuronal dysfunction associated with Alzheimer disease (AD) (PubMed:9338779). Essential for structural and functional integrity of mitochondria (PubMed:20077426) In addition to mitochondrial dehydrogenase activity, moonlights as a component of mitochondrial ribonuclease P, a complex that cleaves tRNA molecules in their 5'-ends (PubMed:18984158, PubMed:24549042, PubMed:25925575, PubMed:26950678, PubMed:28888424). Together with TRMT10C/MRPP1, forms a subcomplex of the mitochondrial ribonuclease P, named MRPP1-MRPP2 subcomplex, which displays functions that are independent of the ribonuclease P activity (PubMed:23042678, PubMed:29040705). The MRPP1-MRPP2 subcomplex catalyzes the formation of N(1)-methylguanine and N(1)-methyladenine at position 9 (m1G9 and m1A9, respectively) in tRNAs; HSD17B10/MRPP2 acting as a non-catalytic subunit (PubMed:23042678, PubMed:25925575, PubMed:28888424). The MRPP1-MRPP2 subcomplex also acts as a tRNA maturation platform: following 5'-end cleavage by the mitochondrial ribonuclease P complex, the MRPP1-MRPP2 subcomplex enhances the efficiency of 3'-processing catalyzed by ELAC2, retains the tRNA product after ELAC2 processing and presents the nascent tRNA to the mitochondrial CCA tRNA nucleotidyltransferase TRNT1 enzyme (PubMed:29040705). Associates with mitochondrial DNA complexes at the nucleoids to initiate RNA processing and ribosome assembly","subcellular_location":"Mitochondrion; Mitochondrion matrix, mitochondrion nucleoid","url":"https://www.uniprot.org/uniprotkb/Q99714/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/HSD17B10","classification":"Not Classified","n_dependent_lines":594,"n_total_lines":1208,"dependency_fraction":0.4917218543046358},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CAPZB","stoichiometry":0.2},{"gene":"G3BP2","stoichiometry":0.2},{"gene":"HSP90B1","stoichiometry":0.2},{"gene":"SSB","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/HSD17B10","total_profiled":1310},"omim":[{"mim_id":"615423","title":"tRNA METHYLTRANSFERASE 10C, MITOCHONDRIAL RNAse P SUBUNIT; TRMT10C","url":"https://www.omim.org/entry/615423"},{"mim_id":"609947","title":"PROTEIN ONLY RNASE P CATALYTIC SUBUNIT; PRORP","url":"https://www.omim.org/entry/609947"},{"mim_id":"309590","title":"INTELLECTUAL DEVELOPMENTAL DISORDER, X-LINKED, SYNDROMIC, TURNER TYPE; MRXST","url":"https://www.omim.org/entry/309590"},{"mim_id":"300705","title":"CHROMOSOME Xp11.22 DUPLICATION SYNDROME","url":"https://www.omim.org/entry/300705"},{"mim_id":"300697","title":"HECT, UBA, AND WWE DOMAINS-CONTAINING PROTEIN 1; HUWE1","url":"https://www.omim.org/entry/300697"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/HSD17B10"},"hgnc":{"alias_symbol":["ERAB","MHBD","17b-HSD10","ABAD","SDR5C1","MRPP2","CAMR"],"prev_symbol":["HADH2","MRXS10"]},"alphafold":{"accession":"Q99714","domains":[{"cath_id":"3.40.50.720","chopping":"11-199_230-252","consensus_level":"high","plddt":98.1546,"start":11,"end":252}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99714","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q99714-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q99714-F1-predicted_aligned_error_v6.png","plddt_mean":96.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=HSD17B10","jax_strain_url":"https://www.jax.org/strain/search?query=HSD17B10"},"sequence":{"accession":"Q99714","fasta_url":"https://rest.uniprot.org/uniprotkb/Q99714.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q99714/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99714"}},"corpus_meta":[{"pmid":"15665036","id":"PMC_15665036","title":"ABAD enhances Abeta-induced cell stress via mitochondrial dysfunction.","date":"2005","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/15665036","citation_count":227,"is_preprint":false},{"pmid":"18252223","id":"PMC_18252223","title":"Submicroscopic duplications of the hydroxysteroid dehydrogenase HSD17B10 and the E3 ubiquitin ligase HUWE1 are associated with mental retardation.","date":"2008","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18252223","citation_count":178,"is_preprint":false},{"pmid":"15910550","id":"PMC_15910550","title":"Mitochondrial dysfunction and Alzheimer's disease: role of amyloid-beta peptide alcohol dehydrogenase (ABAD).","date":"2005","source":"International journal of experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15910550","citation_count":111,"is_preprint":false},{"pmid":"9890977","id":"PMC_9890977","title":"Role of ERAB/L-3-hydroxyacyl-coenzyme A dehydrogenase type II activity in Abeta-induced cytotoxicity.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9890977","citation_count":100,"is_preprint":false},{"pmid":"11023795","id":"PMC_11023795","title":"Recognition of structurally diverse substrates by type II 3-hydroxyacyl-CoA dehydrogenase (HADH II)/amyloid-beta binding alcohol dehydrogenase (ABAD).","date":"2000","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11023795","citation_count":87,"is_preprint":false},{"pmid":"15342248","id":"PMC_15342248","title":"Crystal structure of human ABAD/HSD10 with a bound inhibitor: implications for design of Alzheimer's disease therapeutics.","date":"2004","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15342248","citation_count":86,"is_preprint":false},{"pmid":"10371197","id":"PMC_10371197","title":"Binding of amyloid beta-peptide to mitochondrial hydroxyacyl-CoA dehydrogenase (ERAB): regulation of an SDR enzyme activity with implications for apoptosis in Alzheimer's disease.","date":"1999","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/10371197","citation_count":83,"is_preprint":false},{"pmid":"22127393","id":"PMC_22127393","title":"HSD10 disease: clinical consequences of mutations in the HSD17B10 gene.","date":"2011","source":"Journal of inherited metabolic disease","url":"https://pubmed.ncbi.nlm.nih.gov/22127393","citation_count":68,"is_preprint":false},{"pmid":"23039767","id":"PMC_23039767","title":"Structure-based design and synthesis of benzothiazole phosphonate analogues with inhibitors of human ABAD-Aβ for treatment of Alzheimer's disease.","date":"2012","source":"Chemical biology & drug design","url":"https://pubmed.ncbi.nlm.nih.gov/23039767","citation_count":61,"is_preprint":false},{"pmid":"17253767","id":"PMC_17253767","title":"Surface plasmon resonance and nuclear magnetic resonance studies of ABAD-Abeta interaction.","date":"2007","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17253767","citation_count":59,"is_preprint":false},{"pmid":"17618155","id":"PMC_17618155","title":"HSD17B10: a gene involved in cognitive function through metabolism of isoleucine and neuroactive steroids.","date":"2007","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/17618155","citation_count":58,"is_preprint":false},{"pmid":"25925575","id":"PMC_25925575","title":"Molecular insights into HSD10 disease: impact of SDR5C1 mutations on the human mitochondrial RNase P complex.","date":"2015","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/25925575","citation_count":54,"is_preprint":false},{"pmid":"30444369","id":"PMC_30444369","title":"Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.","date":"2018","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30444369","citation_count":49,"is_preprint":false},{"pmid":"22174920","id":"PMC_22174920","title":"Inhibition of the mitochondrial enzyme ABAD restores the amyloid-β-mediated deregulation of estradiol.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22174920","citation_count":49,"is_preprint":false},{"pmid":"16148061","id":"PMC_16148061","title":"2-Methyl-3-hydroxybutyryl-CoA dehydrogenase (MHBD) deficiency: an X-linked inborn error of isoleucine metabolism that may mimic a mitochondrial disease.","date":"2005","source":"Pediatric research","url":"https://pubmed.ncbi.nlm.nih.gov/16148061","citation_count":43,"is_preprint":false},{"pmid":"19706438","id":"PMC_19706438","title":"Mental retardation linked to mutations in the HSD17B10 gene interfering with neurosteroid and isoleucine metabolism.","date":"2009","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19706438","citation_count":42,"is_preprint":false},{"pmid":"24479630","id":"PMC_24479630","title":"Identification of human ABAD inhibitors for rescuing Aβ-mediated mitochondrial dysfunction.","date":"2014","source":"Current Alzheimer research","url":"https://pubmed.ncbi.nlm.nih.gov/24479630","citation_count":42,"is_preprint":false},{"pmid":"26950678","id":"PMC_26950678","title":"A novel HSD17B10 mutation impairing the activities of the mitochondrial RNase P complex causes X-linked intractable epilepsy and neurodevelopmental regression.","date":"2016","source":"RNA biology","url":"https://pubmed.ncbi.nlm.nih.gov/26950678","citation_count":40,"is_preprint":false},{"pmid":"28888424","id":"PMC_28888424","title":"Novel patient missense mutations in the HSD17B10 gene affect dehydrogenase and mitochondrial tRNA modification functions of the encoded protein.","date":"2017","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/28888424","citation_count":38,"is_preprint":false},{"pmid":"19449377","id":"PMC_19449377","title":"Molecular characterization of the response to chemotherapy in conventional osteosarcomas: predictive value of HSD17B10 and IFITM2.","date":"2009","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19449377","citation_count":38,"is_preprint":false},{"pmid":"25601181","id":"PMC_25601181","title":"Methylene Blue Improves Brain Mitochondrial ABAD Functions and Decreases Aβ in a Neuroinflammatory Alzheimer's Disease Mouse Model.","date":"2015","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/25601181","citation_count":38,"is_preprint":false},{"pmid":"28082069","id":"PMC_28082069","title":"Synthesis and evaluation of frentizole-based indolyl thiourea analogues as MAO/ABAD inhibitors for Alzheimer's disease treatment.","date":"2016","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28082069","citation_count":36,"is_preprint":false},{"pmid":"21382475","id":"PMC_21382475","title":"Behavioral stress causes mitochondrial dysfunction via ABAD up-regulation and aggravates plaque pathology in the brain of a mouse model of Alzheimer disease.","date":"2011","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21382475","citation_count":36,"is_preprint":false},{"pmid":"11430884","id":"PMC_11430884","title":"Deposition of Alzheimer's vascular amyloid-beta is associated with decreased expression of brain L-3-hydroxyacyl-coenzyme A dehydrogenase (ERAB).","date":"2001","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/11430884","citation_count":34,"is_preprint":false},{"pmid":"18996107","id":"PMC_18996107","title":"Study of patients and carriers with 2-methyl-3-hydroxybutyryl-CoA dehydrogenase (MHBD) deficiency: difficulties in the diagnosis.","date":"2008","source":"Clinical biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18996107","citation_count":31,"is_preprint":false},{"pmid":"25352723","id":"PMC_25352723","title":"Molecular docking of fisetin with AD associated AChE, ABAD and BACE1 proteins.","date":"2014","source":"Bioinformation","url":"https://pubmed.ncbi.nlm.nih.gov/25352723","citation_count":29,"is_preprint":false},{"pmid":"31252207","id":"PMC_31252207","title":"ABAD/17β-HSD10 reduction contributes to the protective mechanism of huperzine a on the cerebral mitochondrial function in APP/PS1 mice.","date":"2019","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/31252207","citation_count":27,"is_preprint":false},{"pmid":"27287370","id":"PMC_27287370","title":"Design, synthesis and in vitro evaluation of benzothiazole-based ureas as potential ABAD/17β-HSD10 modulators for Alzheimer's disease treatment.","date":"2016","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/27287370","citation_count":26,"is_preprint":false},{"pmid":"23563466","id":"PMC_23563466","title":"The serological study of cystic echinococcosis and assessment of surgical cases during 5 years (2007-2011) in Khorram Abad, Iran.","date":"2013","source":"Nigerian journal of clinical practice","url":"https://pubmed.ncbi.nlm.nih.gov/23563466","citation_count":25,"is_preprint":false},{"pmid":"29536773","id":"PMC_29536773","title":"1-(Benzo[d]thiazol-2-yl)-3-phenylureas as dual inhibitors of casein kinase 1 and ABAD enzymes for treatment of neurodegenerative disorders.","date":"2018","source":"Journal of enzyme inhibition and medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29536773","citation_count":24,"is_preprint":false},{"pmid":"22132097","id":"PMC_22132097","title":"A novel mutation in the HSD17B10 gene of a 10-year-old boy with refractory epilepsy, choreoathetosis and learning disability.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22132097","citation_count":22,"is_preprint":false},{"pmid":"16899120","id":"PMC_16899120","title":"Comparative evolutionary genomics of the HADH2 gene encoding Abeta-binding alcohol dehydrogenase/17beta-hydroxysteroid dehydrogenase type 10 (ABAD/HSD10).","date":"2006","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/16899120","citation_count":21,"is_preprint":false},{"pmid":"28314118","id":"PMC_28314118","title":"In Vitro Assay Development and HTS of Small-Molecule Human ABAD/17β-HSD10 Inhibitors as Therapeutics in Alzheimer's Disease.","date":"2017","source":"SLAS discovery : advancing life sciences R & D","url":"https://pubmed.ncbi.nlm.nih.gov/28314118","citation_count":18,"is_preprint":false},{"pmid":"32703935","id":"PMC_32703935","title":"Deacetylation of HSD17B10 by SIRT3 regulates cell growth and cell resistance under oxidative and starvation stresses.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/32703935","citation_count":17,"is_preprint":false},{"pmid":"28067167","id":"PMC_28067167","title":"6-benzothiazolyl ureas, thioureas and guanidines are potent inhibitors of ABAD/17β-HSD10 and potential drugs for Alzheimer's disease treatment: Design, synthesis and in vitro evaluation.","date":"2017","source":"Medicinal chemistry (Shariqah (United Arab Emirates))","url":"https://pubmed.ncbi.nlm.nih.gov/28067167","citation_count":17,"is_preprint":false},{"pmid":"39038923","id":"PMC_39038923","title":"Astragaloside IV protects renal tubular epithelial cells against oxidative stress-induced injury by upregulating CPT1A-mediated HSD17B10 lysine succinylation in diabetic kidney disease.","date":"2024","source":"Phytotherapy research : PTR","url":"https://pubmed.ncbi.nlm.nih.gov/39038923","citation_count":14,"is_preprint":false},{"pmid":"28875337","id":"PMC_28875337","title":"Clinical and molecular analysis of 6 Chinese patients with isoleucine metabolism defects: identification of 3 novel mutations in the HSD17B10 and ACAT1 gene.","date":"2017","source":"Metabolic brain disease","url":"https://pubmed.ncbi.nlm.nih.gov/28875337","citation_count":12,"is_preprint":false},{"pmid":"9851691","id":"PMC_9851691","title":"The gene for the Alzheimer-associated beta-amyloid-binding protein (ERAB) is differentially expressed in the testicular Leydig cells of the azoospermic by w/w(v) mouse.","date":"1998","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9851691","citation_count":12,"is_preprint":false},{"pmid":"23266819","id":"PMC_23266819","title":"A 5-methylcytosine hotspot responsible for the prevalent HSD17B10 mutation.","date":"2012","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/23266819","citation_count":10,"is_preprint":false},{"pmid":"20664630","id":"PMC_20664630","title":"X-inactivation of HSD17B10 revealed by cDNA analysis in two female patients with 17β-hydroxysteroid dehydrogenase 10 deficiency.","date":"2010","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/20664630","citation_count":10,"is_preprint":false},{"pmid":"9712734","id":"PMC_9712734","title":"ERAB contains a putative noncleavable signal peptide.","date":"1998","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9712734","citation_count":10,"is_preprint":false},{"pmid":"18835182","id":"PMC_18835182","title":"Molecular dynamics simulations of the amyloid-beta binding alcohol dehydrogenase (ABAD) enzyme.","date":"2008","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18835182","citation_count":10,"is_preprint":false},{"pmid":"19601895","id":"PMC_19601895","title":"ABAD: a potential therapeutic target for Abeta-induced mitochondrial dysfunction in Alzheimer's disease.","date":"2009","source":"Mini reviews in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19601895","citation_count":10,"is_preprint":false},{"pmid":"17917077","id":"PMC_17917077","title":"Stable expression of a novel fusion peptide of thioredoxin-1 and ABAD-inhibiting peptide protects PC12 cells from intracellular amyloid-beta.","date":"2007","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/17917077","citation_count":9,"is_preprint":false},{"pmid":"23755257","id":"PMC_23755257","title":"The amyloid-β-SDR5C1(ABAD) interaction does not mediate a specific inhibition of mitochondrial RNase P.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23755257","citation_count":8,"is_preprint":false},{"pmid":"23834306","id":"PMC_23834306","title":"Transcription start sites and epigenetic analysis of the HSD17B10 proximal promoter.","date":"2013","source":"BMC biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23834306","citation_count":8,"is_preprint":false},{"pmid":"28660722","id":"PMC_28660722","title":"In silico-designed novel non-peptidic ABAD LD hot spot mimetics reverse Aβ-induced mitochondrial impairments in vitro.","date":"2017","source":"Chemical biology & drug design","url":"https://pubmed.ncbi.nlm.nih.gov/28660722","citation_count":8,"is_preprint":false},{"pmid":"32381089","id":"PMC_32381089","title":"Xp11.22 duplications in four unrelated Chinese families: delineating the genotype-phenotype relationship for HSD17B10 and FGD1.","date":"2020","source":"BMC medical genomics","url":"https://pubmed.ncbi.nlm.nih.gov/32381089","citation_count":7,"is_preprint":false},{"pmid":"40484144","id":"PMC_40484144","title":"Peptide-loaded chitosan nanoparticles improve mitochondrial and cognitive functions via inhibition of Aβ-ABAD interaction in Alzheimer's disease.","date":"2025","source":"European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V","url":"https://pubmed.ncbi.nlm.nih.gov/40484144","citation_count":5,"is_preprint":false},{"pmid":"38841322","id":"PMC_38841322","title":"Novel Mutation in the HSD17B10 Gene Accompanied by Dysmorphic Findings in Female Patients.","date":"2024","source":"Molecular syndromology","url":"https://pubmed.ncbi.nlm.nih.gov/38841322","citation_count":4,"is_preprint":false},{"pmid":"10781884","id":"PMC_10781884","title":"Lack of quinone reductase activity suggests that amyloid-beta peptide/ERAB induced lipid peroxidation is not directly related to production of reactive oxygen species by redoxcycling.","date":"2000","source":"Toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/10781884","citation_count":4,"is_preprint":false},{"pmid":"40055822","id":"PMC_40055822","title":"A novel c.59 C > T variant of the HSD17B10 gene as a possible cause of the neonatal form of HSD10 mitochondrial disease with hepatic dysfunction: a case report and review of the literature.","date":"2025","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/40055822","citation_count":3,"is_preprint":false},{"pmid":"20735667","id":"PMC_20735667","title":"Comments on 'Significance of developmental expression of amphioxus Branchiostoma belcheri and zebrafish Danio rerio Hsd17b10 in biological and medical research'.","date":"2009","source":"Journal of fish biology","url":"https://pubmed.ncbi.nlm.nih.gov/20735667","citation_count":3,"is_preprint":false},{"pmid":"25206842","id":"PMC_25206842","title":"rAAV/ABAD-DP-6His attenuates oxidative stress-induced injury of PC12 cells.","date":"2014","source":"Neural regeneration research","url":"https://pubmed.ncbi.nlm.nih.gov/25206842","citation_count":3,"is_preprint":false},{"pmid":"23251955","id":"PMC_23251955","title":"[Mitochondrial enzyme ABAD and its role in the development and treatment of Alzheimer's disease].","date":"2012","source":"Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti","url":"https://pubmed.ncbi.nlm.nih.gov/23251955","citation_count":1,"is_preprint":false},{"pmid":"22490659","id":"PMC_22490659","title":"[Cloning and expression of fusion gene of amyloid beta binding alcohol dehydrogenase decoy peptide aptamer (TRX1-ABAD-DP-TRX2)].","date":"2012","source":"Zhonghua yi xue za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/22490659","citation_count":1,"is_preprint":false},{"pmid":"38684297","id":"PMC_38684297","title":"[Clinical analysis and genetic diagnosis of three children with Isoleucine metabolic disorders due to variants of HSD17B10 and ACAT1 genes].","date":"2024","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/38684297","citation_count":0,"is_preprint":false},{"pmid":"41971928","id":"PMC_41971928","title":"Adult case of 17β-hydroxysteroid dehydrogenase type 10 (HSD10) deficiency due to the p. Arg130Cys mutation of the HSD17B10 gene: case report.","date":"2026","source":"AME case reports","url":"https://pubmed.ncbi.nlm.nih.gov/41971928","citation_count":0,"is_preprint":false},{"pmid":"11798857","id":"PMC_11798857","title":"[Analysis of the polymorphisms of the AACT, ERAB and NACP genes in 15 patients with Alzheimer's disease].","date":"2001","source":"Zhonghua yi xue za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/11798857","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":29835,"output_tokens":5117,"usd":0.08313,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":13539,"output_tokens":5539,"usd":0.103085,"stage2_stop_reason":"end_turn"},"total_usd":0.186215,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"ERAB/HSD17B10 (HADH II) catalyzes NADH-dependent reduction of S-acetoacetyl-CoA (Km ~68 µM, Vmax ~430 µmol/min/mg), oxidation of 17β-estradiol, and oxidation of a variety of simple alcohols (C2–C10) in the presence of NAD+. Active-site mutagenesis (Y168G/K172G) abolished both enzymatic activity and Aβ-mediated cytotoxicity and prevented generation of malondialdehyde-protein and 4-hydroxynonenal adducts, establishing that the generalized alcohol dehydrogenase activity is required for Aβ-induced cell death.\",\n      \"method\": \"In vitro enzyme kinetics with purified recombinant protein; site-directed mutagenesis of catalytic domain; cell transfection assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with kinetics, active-site mutagenesis, and cellular functional validation in a single study\",\n      \"pmids\": [\"9890977\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Aβ peptide inhibits ERAB/HSD17B10 hydroxyacyl-CoA dehydrogenase activity in a mixed-type fashion (Ki ~1.2 µM using 3-hydroxybutyryl-CoA as substrate; KiES ~0.3 µM). The region of Aβ comprising residues 12–24 is required for inhibition. ERAB is localized to endoplasmic reticulum and mitochondria.\",\n      \"method\": \"In vitro enzyme inhibition kinetics with recombinant ERAB; peptide fragment analysis; subcellular fractionation/localization\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro enzyme kinetics with mechanistic inhibition analysis, replicated binding observations across multiple studies\",\n      \"pmids\": [\"10371197\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Crystal structures of rat HADH II/ABAD were determined as: (1) binary complex with NADH at 2.0 Å, (2) ternary complex with NAD+ and 3-ketobutyrate at 1.4 Å, and (3) ternary complex with NADH and 17β-estradiol at 1.7 Å. The enzyme is a short-chain hydroxysteroid dehydrogenase with a Rossman fold. Ketobutyrate binding triggers closure of the active-site specificity loop; steroid substrate does not require loop closure. Rat HADH II/ABAD binds Aβ(1-40) with KD ~21 nM.\",\n      \"method\": \"X-ray crystallography; in vitro binding assay\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple high-resolution crystal structures with functional mechanistic interpretation, Aβ binding confirmed biophysically\",\n      \"pmids\": [\"11023795\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Crystal structure of human ABAD/HSD10 complexed with NAD+ and a small-molecule inhibitor revealed that the inhibitor occupies the substrate-binding site and forms a covalent adduct with the NAD+ cofactor, thereby blocking enzymatic activity.\",\n      \"method\": \"X-ray crystallography\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — high-resolution crystal structure with mechanistic interpretation of inhibitor binding mode\",\n      \"pmids\": [\"15342248\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"In neurons from transgenic mice overexpressing both mutant APP and ABAD (Tg mAPP/ABAD), ABAD potentiates Aβ-induced mitochondrial dysfunction: spontaneous generation of H2O2 and superoxide, decreased ATP, cytochrome c release, caspase-3 activation, DNA fragmentation, and selective reduction of mitochondrial complex IV (cytochrome c oxidase, COX) activity. These changes were not present in Tg ABAD or Tg mAPP single-transgenic mice, establishing ABAD as a cofactor linking Aβ to mitochondrial oxidant stress.\",\n      \"method\": \"Transgenic mouse model (double vs single transgenic genetic epistasis); ROS assays; COX activity measurement; ATP quantification; cytochrome c release assay; caspase activity assay\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal functional readouts in a well-controlled genetic epistasis model, replicated in vivo and in vitro\",\n      \"pmids\": [\"15665036\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Surface plasmon resonance thermodynamic analysis showed that ABAD–Aβ association is driven by a favorable entropic change (ΔS = 300 ± 30 J mol−1 K−1) overcoming an unfavorable enthalpy (ΔH = 49 ± 7 kJ/mol), indicating hydrophobic interactions dominate. Saturation transfer difference NMR directly demonstrated that Aβ binding inhibits ABAD–NAD interaction, and conversely NAD inhibits Aβ binding, establishing that Aβ and NAD binding to ABAD are mutually exclusive. Aβ binding induces conformational changes in ABAD.\",\n      \"method\": \"Surface plasmon resonance (SPR) thermodynamic analysis; saturation transfer difference (STD) NMR\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — two orthogonal biophysical methods (SPR and NMR) in a single study establishing the mechanism of NAD/Aβ competition\",\n      \"pmids\": [\"17253767\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"HSD17B10 encodes a mitochondrial multifunctional enzyme (HSD10) that catalyzes the 2-methyl-3-hydroxybutyryl-CoA dehydrogenation step in isoleucine catabolism and inactivates positive modulators of GABAA receptors (neuroactive steroids such as allopregnanolone). Missense mutations causing X-linked mental retardation and HSD10 deficiency impair these enzymatic functions.\",\n      \"method\": \"Enzyme activity assays on patient-derived samples; molecular genetic analysis\",\n      \"journal\": \"Molecular genetics and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical enzyme assays in patient cells with genetic validation, single lab review/original compilation\",\n      \"pmids\": [\"17618155\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The HSD10 E249Q mutation impairs subunit interactions, yielding allosteric enzyme kinetics (Hill coefficient ~1.3 for allopregnanolone oxidation). HSD10(E249Q) fails to catalyze dehydrogenation of 2-methyl-3-hydroxybutyryl-CoA and oxidation of allopregnanolone at low substrate concentrations, linking neurosteroid metabolic dysfunction—not isoleucine catabolism alone—to the neurological phenotype.\",\n      \"method\": \"Recombinant mutant protein expression; enzyme kinetics; comparison with wild-type activity\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with patient-derived mutations and kinetic analysis establishing allosteric mechanism\",\n      \"pmids\": [\"19706438\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"HSD17B10 is an essential component of the mitochondrial RNase P complex, which removes 5'-extensions from mitochondrial tRNA precursors (tRNA processing). It also participates in the RNase P subcomplex that catalyzes N1-methylation of purines at position 9 of mitochondrial tRNAs.\",\n      \"method\": \"Biochemical characterization of the mitochondrial RNase P complex; tRNA processing assays\",\n      \"journal\": \"Journal of inherited metabolic disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional biochemical assays describing the role within a characterized complex, referenced from primary biochemical work\",\n      \"pmids\": [\"22127393\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"The AG18051 small-molecule inhibitor partially blocks the Aβ–ABAD interaction (pull-down assay), prevents Aβ42-induced downregulation of ABAD's estradiol-producing activity (used as a functional readout), reduces Aβ42-induced mitochondrial respiration impairment, and reduces ROS, establishing that ABAD enzymatic activity contributes to Aβ toxicity through disruption of estradiol homeostasis in neurons.\",\n      \"method\": \"Pull-down assay; ABAD enzyme activity assay (estradiol measurement); mitochondrial respiration assay; ROS measurement; cell viability assays\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal functional assays in a single study, single lab\",\n      \"pmids\": [\"22174920\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Negative finding: Micromolar concentrations of monomeric or oligomerized Aβ inhibit mitochondrial tRNA 5'-end processing and position-9 methylation by the SDR5C1 (HSD17B10)-containing RNase P complex, but the same concentrations also inhibit related RNase P and methyltransferase activities that do NOT contain an SDR5C1 homolog. Therefore, the deleterious effect of Aβ on mitochondrial function cannot be explained by specific inhibition of the mitochondrial RNase P or its tRNA:m1R9 methyltransferase subcomplex via SDR5C1.\",\n      \"method\": \"In vitro RNase P and methyltransferase activity assays with recombinant components and Aβ titration\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — rigorous in vitro reconstitution with appropriate controls demonstrating non-specificity; mechanistically informative negative result\",\n      \"pmids\": [\"23755257\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Pathogenic missense mutations in SDR5C1/HSD17B10 (HSD10 disease mutations) impair: (1) SDR5C1-dependent dehydrogenase activity, (2) mitochondrial tRNA 5'-end processing by the RNase P complex, and (3) N1-methylation of purines at tRNA position 9. Some mutations disrupt SDR5C1 homotetramerization and/or impair its interaction with TRMT10C (the methyltransferase subunit of mitochondrial RNase P).\",\n      \"method\": \"Recombinant mutant protein expression and biochemical characterization; tRNA processing assays; methyltransferase assays; protein–protein interaction assays\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with multiple patient mutations, multiple orthogonal assays (dehydrogenase, tRNA processing, methylation, protein interactions)\",\n      \"pmids\": [\"25925575\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"A novel p.K212E mutation in HSD17B10 impairs SDR5C1-dependent mitochondrial RNase P activities (tRNA 5'-processing and position-9 methylation), but does not abolish dehydrogenase activity or MHBD function, indicating that pathogenicity in this case is due to impaired mitochondrial tRNA maturation rather than metabolic enzyme deficiency.\",\n      \"method\": \"In vitro tRNA processing and methylation assays with recombinant mutant protein; patient exome sequencing\",\n      \"journal\": \"RNA biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with patient mutation, multiple functional assays separating the two known functions\",\n      \"pmids\": [\"26950678\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Two novel patient mutations (p.V12L and p.V176M) in HSD17B10 reduce dehydrogenase activity, mitochondrial tRNA methyltransferase activity, and tRNA 5'-processing activity in vitro. p.V12L reduces protein stability; p.V176M impairs kinetics and TRMT10C/MRPP1 complex formation, revealing two distinct molecular mechanisms for pathogenic mutations.\",\n      \"method\": \"Recombinant mutant protein expression; enzyme kinetics; tRNA processing and methylation assays; protein stability and complex formation assays\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular basis of disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — rigorous in vitro biochemical characterization with multiple orthogonal assays for two independent patient mutations\",\n      \"pmids\": [\"28888424\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"HSD17B10 is acetylated at K79, K99, and K105 by the acetyltransferase CBP, and deacetylated by SIRT3. Acetylation of HSD17B10 regulates its dehydrogenase enzymatic activity and the formation of the mitochondrial RNase P complex. HSD17B10 acetylation state also affects cell growth and cell resistance under oxidative and starvation stress conditions.\",\n      \"method\": \"Co-IP; mass spectrometry identification of acetylation sites; site-directed mutagenesis; in vitro enzyme activity assay; cell-based functional assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP, mutagenesis, and functional assays; single lab, multiple methods\",\n      \"pmids\": [\"32703935\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"HSD17B10 is succinylated at K99 by CPT1A. K99 succinylation maintains mitochondrial RNase P (MRPP1 complex) stability, and the K99R mutation disrupts HSD17B10 binding to CPT1A and MRPP1, impairs RNase P activity, and induces oxidative stress. ASIV restores CPT1A activity and K99 succinylation of HSD17B10, thereby preserving RNase P function in tubular epithelial cells.\",\n      \"method\": \"Succinylated proteomics; molecular docking; cell thermal shift assay; molecular dynamics simulation; site-directed mutagenesis (K99R); Co-IP; in vitro RNase P activity assay; in vivo mouse model\",\n      \"journal\": \"Phytotherapy research : PTR\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple methods including proteomics, mutagenesis, and functional assays; single lab\",\n      \"pmids\": [\"39038923\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Negative finding: Recombinant human ERAB/HSD17B10 showed no quinone reductase activity against several orthoquinones, with or without Aβ, indicating that Aβ-ERAB-induced lipid peroxidation observed in vivo is not mediated by quinone redox cycling.\",\n      \"method\": \"In vitro enzyme assay with recombinant human ERAB and orthoquinone substrates\",\n      \"journal\": \"Toxicology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro assay, single lab, but mechanistically informative negative result\",\n      \"pmids\": [\"10781884\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"ERAB/HSD17B10 contains a putative signal peptide sequence (identified by computational and comparative analysis across human, rodent, and bovine sequences) suggesting it is a type II integral membrane protein in vertebrates, potentially explaining its localization in secretory organelles and ability to bind Aβ.\",\n      \"method\": \"Computational sequence analysis; comparative vertebrate analysis\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 / Weak — computational prediction only, no direct experimental validation of topology\",\n      \"pmids\": [\"9712734\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Behavioral stress (restraint) upregulates ABAD expression in mitochondria of the brain of Tg-APPswe/PS1dE9 mice. Knockdown of ABAD by siRNA in SH-SY5Y cells suppresses glucocorticoid-enhanced mitochondrial dysfunction and ROS accumulation, establishing that ABAD upregulation is required for stress-induced mitochondrial dysfunction in the context of Aβ pathology.\",\n      \"method\": \"siRNA knockdown; mitochondrial dysfunction assays; ROS measurement; transgenic mouse model\",\n      \"journal\": \"Free radical biology & medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function (siRNA) with defined functional readouts plus in vivo validation; single lab\",\n      \"pmids\": [\"21382475\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"HSD17B10 (ABAD/SDR5C1/MRPP2) is a mitochondrial short-chain dehydrogenase/reductase that functions as: (1) a metabolic enzyme catalyzing NAD+-dependent oxidation of 3-hydroxyacyl-CoA derivatives, neuroactive steroids (allopregnanolone, 17β-estradiol), and branched-chain fatty acid intermediates (including the MHBD step of isoleucine catabolism); (2) an essential structural and catalytic subunit of human mitochondrial RNase P, which cleaves 5'-extensions of mitochondrial tRNA precursors and methylates purines at tRNA position 9 (as part of the TRMT10C/MRPP1 subcomplex); and (3) an intracellular binding partner of Aβ peptide—interaction that is mutually exclusive with NAD+ binding, distorts the enzyme's structure, impairs its catalytic activity, and promotes mitochondrial oxidant stress and complex IV dysfunction; its enzymatic activity is regulated post-translationally by SIRT3-mediated deacetylation (at K79/K99/K105) and CPT1A-mediated K99 succinylation, both of which modulate its dehydrogenase activity and RNase P complex assembly.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"HSD17B10 (ABAD/ERAB/SDR5C1/MRPP2) is a mitochondrial short-chain dehydrogenase/reductase that operates as a moonlighting enzyme bridging mitochondrial metabolism and tRNA maturation [#0, #8]. As a metabolic enzyme it adopts a Rossmann-fold and catalyzes NAD(H)-dependent reactions including reduction of S-acetoacetyl-CoA, oxidation of 3-hydroxyacyl-CoA derivatives, oxidation of 17\\u03b2-estradiol, and broad-spectrum alcohol dehydrogenase activity, with ketobutyrate binding triggering closure of an active-site specificity loop [#0, #2]. In isoleucine catabolism it performs the 2-methyl-3-hydroxybutyryl-CoA dehydrogenation step and also inactivates GABAA-modulating neuroactive steroids such as allopregnanolone [#6, #7]. Independently of its catalytic activity, HSD17B10 is an essential homotetrameric subunit of mitochondrial RNase P, where together with TRMT10C/MRPP1 it enables 5'-end processing of mitochondrial tRNA precursors and N1-methylation of purines at tRNA position 9 [#8, #11]. Both functions are tuned post-translationally: SIRT3 deacetylates K79/K99/K105 (acetylated by CBP) and CPT1A succinylates K99 to regulate dehydrogenase activity and RNase P complex assembly [#14, #15]. Pathogenic missense mutations causing X-linked HSD10 disease impair these activities through distinct mechanisms\\u2014loss of dehydrogenase/MHBD activity, disrupted homotetramerization, reduced stability, or impaired TRMT10C binding and tRNA maturation\\u2014establishing that either metabolic or RNase P dysfunction can drive the neurological phenotype [#7, #11, #12, #13]. HSD17B10 also binds A\\u03b2 peptide via a hydrophobically-driven interaction (KD ~21 nM) that is mutually exclusive with NAD+, distorts the enzyme, and potentiates A\\u03b2-induced mitochondrial oxidant stress, cytochrome c release, and selective complex IV deficiency [#2, #4, #5]; controlled in vitro work establishes that A\\u03b2 inhibition of RNase P is not SDR5C1-specific and therefore does not account for this toxicity [#10].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Established that HSD17B10 is a catalytically active NAD(H)-dependent dehydrogenase and that this enzymatic activity is mechanistically required for A\\u03b2-induced cytotoxicity, linking an enzyme to neurodegenerative cell death.\",\n      \"evidence\": \"In vitro enzyme kinetics with recombinant protein, active-site mutagenesis (Y168G/K172G), and cell transfection cytotoxicity assays\",\n      \"pmids\": [\"9890977\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve which physiological substrate mediates toxicity\", \"Mechanism connecting catalysis to lipid peroxidation adducts left undefined\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Defined the kinetic mode of A\\u03b2 inhibition of HSD17B10 and the A\\u03b2 region required, framing the enzyme as a direct intracellular A\\u03b2 target.\",\n      \"evidence\": \"In vitro enzyme inhibition kinetics with 3-hydroxybutyryl-CoA, A\\u03b2 peptide fragment analysis, and subcellular fractionation\",\n      \"pmids\": [\"10371197\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"ER vs mitochondrial localization not reconciled with later mitochondrial assignment\", \"Structural basis of A\\u03b2 binding not yet defined\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Solved the catalytic architecture, showing a Rossmann-fold dehydrogenase with a substrate-specificity loop and quantifying high-affinity A\\u03b2 binding, providing structural mechanism for cofactor and substrate handling.\",\n      \"evidence\": \"X-ray crystallography of binary and ternary complexes (NADH, NAD+/3-ketobutyrate, NADH/17\\u03b2-estradiol) plus in vitro A\\u03b2 binding\",\n      \"pmids\": [\"11023795\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"A\\u03b2 binding site not mapped on the structure\", \"Human enzyme structure not yet determined here (rat ortholog)\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Ruled out quinone redox cycling as the source of A\\u03b2-ABAD-induced lipid peroxidation, narrowing candidate toxicity mechanisms.\",\n      \"evidence\": \"In vitro orthoquinone reductase assays with recombinant human ERAB +/- A\\u03b2\",\n      \"pmids\": [\"10781884\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Negative result does not identify the actual oxidant-generating mechanism\", \"Single lab in vitro assay\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Demonstrated a druggable active site by capturing an inhibitor forming a covalent adduct with the NAD+ cofactor in the human enzyme, establishing a structural strategy to block activity.\",\n      \"evidence\": \"X-ray crystallography of human ABAD with NAD+ and a small-molecule inhibitor\",\n      \"pmids\": [\"15342248\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular efficacy of inhibitor not addressed in this structural study\", \"Selectivity over other SDRs not established\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Provided in vivo genetic proof that ABAD acts as a cofactor converting A\\u03b2 into mitochondrial dysfunction, including selective complex IV loss.\",\n      \"evidence\": \"Double vs single transgenic mouse epistasis (mAPP/ABAD), ROS, COX activity, ATP, cytochrome c release, caspase-3 assays\",\n      \"pmids\": [\"15665036\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular cause of selective complex IV vulnerability not defined\", \"Did not distinguish loss of enzyme function from gain of toxic complex\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Resolved the thermodynamics and exclusivity of A\\u03b2 binding, showing hydrophobically-driven A\\u03b2 association is mutually exclusive with NAD+, defining a competitive inactivation mechanism.\",\n      \"evidence\": \"Surface plasmon resonance thermodynamics and saturation transfer difference NMR\",\n      \"pmids\": [\"17253767\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Atomic-resolution A\\u03b2-bound structure still lacking\", \"Quantitative contribution of conformational distortion to toxicity unquantified\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Connected HSD17B10 metabolic functions\\u2014isoleucine catabolism and neurosteroid inactivation\\u2014to X-linked mental retardation/HSD10 deficiency, broadening its physiological remit beyond Alzheimer biology.\",\n      \"evidence\": \"Enzyme activity assays on patient-derived samples and molecular genetic analysis\",\n      \"pmids\": [\"17618155\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative contribution of each metabolic function to disease unresolved\", \"Compilation-style evidence rather than single reconstitution\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Showed a disease mutation can disrupt subunit interactions and confer allosteric kinetics, implicating neurosteroid metabolic failure rather than isoleucine catabolism alone in pathology.\",\n      \"evidence\": \"Recombinant E249Q mutant kinetics (Hill coefficient ~1.3) versus wild-type\",\n      \"pmids\": [\"19706438\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo neurosteroid levels in patients not measured here\", \"Generalizability to other mutations not tested\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Established a wholly distinct, non-metabolic role for HSD17B10 as an essential subunit of mitochondrial RNase P, coupling it to tRNA 5'-processing and position-9 methylation.\",\n      \"evidence\": \"Biochemical characterization of the mitochondrial RNase P complex and tRNA processing assays\",\n      \"pmids\": [\"22127393\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Catalytic vs structural contribution of HSD17B10 to RNase P not separated\", \"Stoichiometry within the complex not defined here\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Provided loss-of-function evidence that ABAD upregulation is required for stress-induced mitochondrial dysfunction under A\\u03b2 pathology, linking glucocorticoid stress to the ABAD-A\\u03b2 axis.\",\n      \"evidence\": \"siRNA knockdown in SH-SY5Y cells, ROS and mitochondrial dysfunction assays, plus Tg-APPswe/PS1dE9 mouse model\",\n      \"pmids\": [\"21382475\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Transcriptional mechanism of stress-induced ABAD upregulation unknown\", \"Single cell line for knockdown\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Showed a small-molecule disruptor of the A\\u03b2-ABAD interaction rescues mitochondrial respiration and estradiol homeostasis, supporting enzymatic activity as a therapeutic node in A\\u03b2 toxicity.\",\n      \"evidence\": \"Pull-down, estradiol-based enzyme activity readout, mitochondrial respiration, ROS, and viability assays with AG18051\",\n      \"pmids\": [\"22174920\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Only partial blockade of interaction achieved\", \"In vivo efficacy not tested; single lab\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstrated that A\\u03b2 inhibition of the SDR5C1-containing RNase P is non-specific, excluding RNase P inhibition as the mechanism of A\\u03b2 mitochondrial toxicity.\",\n      \"evidence\": \"In vitro RNase P and methyltransferase assays comparing SDR5C1-containing and non-SDR5C1 complexes with A\\u03b2 titration\",\n      \"pmids\": [\"23755257\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not identify the bona fide A\\u03b2 target for mitochondrial dysfunction\", \"Confined to in vitro reconstituted activities\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Unified the disease mechanism by showing pathogenic mutations simultaneously impair dehydrogenase activity, RNase P tRNA processing, methylation, homotetramerization, and TRMT10C interaction.\",\n      \"evidence\": \"Recombinant mutant proteins with dehydrogenase, tRNA processing, methyltransferase, and protein interaction assays\",\n      \"pmids\": [\"25925575\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which deficit dominates clinically per mutation not resolved\", \"Structural basis of disrupted tetramerization not shown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Dissociated the two functions in vivo by identifying a mutation (K212E) that impairs RNase P activities while sparing dehydrogenase/MHBD function, proving tRNA maturation defects alone can be pathogenic.\",\n      \"evidence\": \"In vitro tRNA processing and methylation assays with recombinant K212E and patient exome sequencing\",\n      \"pmids\": [\"26950678\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How a single residue selectively affects RNase P but not catalysis structurally unexplained\", \"Single patient\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Defined two distinct molecular routes to pathogenicity\\u2014protein destabilization versus impaired kinetics and complex formation\\u2014for additional patient mutations.\",\n      \"evidence\": \"Recombinant V12L and V176M mutant kinetics, tRNA processing/methylation, stability, and MRPP1 complex formation assays\",\n      \"pmids\": [\"28888424\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo consequences of each mechanism not measured\", \"Limited to two mutations\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Revealed post-translational acetylation control of HSD17B10, with CBP and SIRT3 setting K79/K99/K105 acetylation to regulate both dehydrogenase activity and RNase P assembly and stress resistance.\",\n      \"evidence\": \"Co-IP, mass spectrometry site mapping, site-directed mutagenesis, in vitro activity, and cell-based stress assays\",\n      \"pmids\": [\"32703935\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological stimuli driving acetylation changes not defined\", \"Single lab; in vivo relevance untested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Added a second PTM layer by showing CPT1A-mediated K99 succinylation maintains RNase P (MRPP1) stability and protects against oxidative stress in tubular epithelial cells.\",\n      \"evidence\": \"Succinyl-proteomics, docking, thermal shift, MD simulation, K99R mutagenesis, Co-IP, RNase P activity, and mouse model\",\n      \"pmids\": [\"39038923\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Interplay between K99 acetylation and succinylation unresolved\", \"Single lab; mechanism of CPT1A targeting to HSD17B10 unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The bona fide intracellular substrate and molecular event by which A\\u03b2 binding to HSD17B10 selectively impairs complex IV and drives oxidant stress remains unidentified.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"RNase P inhibition excluded as the toxic mechanism\", \"No atomic-resolution A\\u03b2-bound HSD17B10 structure\", \"Causal substrate linking catalysis to mitochondrial damage undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [0, 2, 6, 7]},\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [8, 11]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [8, 11]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [1, 4, 8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [8, 11]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 6, 7]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [4, 11]}\n    ],\n    \"complexes\": [\n      \"mitochondrial RNase P\"\n    ],\n    \"partners\": [\n      \"TRMT10C\",\n      \"CPT1A\",\n      \"SIRT3\",\n      \"CBP\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}